biote Q4 2024 revenue up 9% to $49.8M; EPS falls to $0.10 from $0.18

biote Corp.

Q4 2024 revenue $49.8M, procedure revenue $36.6M, net income $3.5M ($0.10 EPS) vs $12.1M ($0.18 EPS) a year ago.
Full year 2024 revenue $197.2M (+6.4% YoY); net income $0.05M (vs net loss $2.8M in 2023).
Adjusted EBITDA Q4 $15.1M (30.3% margin); full year $58.2M (29.5% margin).
Gross profit margin improved to 71.8% Q4 (70.5% full year) on vertical integration of 503B facility.
Cash and cash equivalents $39.3M at year-end; fiscal 2025 outlook provided but not detailed in excerpt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.